Celltrion Healthcare's Truxima (rituximab biosimilar)

Truxima is a medicine made by Celltrion Healthcare that mimics rituximab, a targeted therapy used to treat certain cancers and autoimmune diseases like lymphoma and rheumatoid arthritis. As a biosimilar, it provides a similar biological effect to the original drug but typically at a lower cost. Truxima works by targeting and destroying specific cells involved in these diseases, helping to reduce symptoms and manage disease progression. It is approved for use where rituximab is prescribed and offers an effective alternative to the branded version, supporting broader access to essential treatments.